Company Overview
OnKure Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. The company functions within the healthcare sector, specifically inside the biotechnology industry, which implies a focus on high-risk, high-reward research and development rather than mature commercial product sales. Its market capitalization stands at $54.56M, with a workforce comprising 45 employees, reflecting the typical lean operational structure of a pre-commercialization biotech firm. The absence of reported annual revenue alongside this market cap indicates that the company's valuation is derived entirely from its potential future product candidates, such as OKI-219, rather than current cash flows, positioning it as an early-stage asset reliant on clinical trial success to generate future value.
Financial Health
The company reports revenue of N/A for the trailing twelve months, a net income of $-59,517,000, and an EBITDA of $-62,503,000, highlighting a significant operational deficit where the gap between revenue and net income reveals a cost structure dominated by research and development expenses rather than cost of goods sold. Free cash flow stands at $-31,100,750, which indicates that the company is burning cash to fund its clinical pipeline and lacks the financial flexibility to sustain operations without further capital raising or external funding. All three margins—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that indicates the company has not yet achieved commercial profitability and that any revenue generated would currently not cover its operating costs. On the balance sheet, the company holds $59.05M in cash against $549,000 in debt, resulting in a debt-to-equity ratio of 0.98, which suggests a relatively conservative leverage profile given the minimal debt load relative to equity. The current ratio is listed at 10.28, a metric that indicates extremely strong short-term liquidity and the ability to cover current liabilities many times over, providing a substantial buffer for ongoing R&D expenditures. Return on Equity is -74.4% and Return on Assets is -44.5%, metrics that reveal that management has not yet generated positive returns on its capital base, a common characteristic for clinical-stage entities that are still in the investment phase.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed at -1.40, a discrepancy that implies the market is pricing the stock based on future expectations of profitability that have not yet materialized in current financial statements. The price-to-book ratio is 0.97, indicating that the market values the company at roughly parity with its book value, suggesting no significant premium or discount relative to the net asset position. The price-to-sales ratio is N/A and the EV/EBITDA stands at 0.06, metrics that suggest traditional valuation multiples are not applicable for a company with no revenue and near-zero EBITDA, forcing investors to rely on clinical milestones for valuation logic. The 52-week high is $5.10 and the 52-week low is $1.70; without a specific current price provided in the facts, the stock's position within this range cannot be numerically calculated but the range demonstrates a wide trading band typical of speculative biotech equities. The beta value is N/A, meaning volatility data relative to the broader market is not available for this specific ticker in the current dataset, making it impossible to quantify the stock's sensitivity to general market fluctuations.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient commercial revenue to calculate meaningful growth rates for the trailing twelve months. Since the company does not pay a dividend, the dividend yield and payout ratio are both N/A or 0.0% respectively, indicating that the company reinvests all available resources and potential earnings back into its R&D pipeline rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current financial metrics, as the company is in a stage where growth is defined by clinical trial progression rather than percentage increases in revenue or earnings. Consequently, the income profile is non-existent in the current period, with the entire financial focus directed toward capitalizing on the potential of its lead product candidate, OKI-219.